PROTARA THERAPEUTIC INC (TARA) Stock News

USA - NASDAQ:TARA - US74365U1079 - Common Stock

3.03 USD

-0.04 (-1.3%)

Last: 9/17/2025, 8:06:31 PM

3.03 USD

0 (0%)

After Hours: 9/17/2025, 8:06:31 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TARA Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Protara Therapeutics

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

21 days ago - By: Benzinga - Mentions: IVA BOLT ENGN RLMD ...

12 Health Care Stocks Moving In Thursday's After-Market Session

22 days ago - By: Protara Therapeutics

Protara Therapeutics to Participate in Upcoming Investor Conferences

a month ago - By: The Motley Fool

Protara Beats Q2 Loss Estimates

a month ago - By: Protara Therapeutics

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Protara Therapeutics

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Protara Therapeutics

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Protara Therapeutics

Protara Therapeutics Announces Addition to the Russell 3000® Index

4 months ago - By: Protara Therapeutics

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

4 months ago - By: Protara Therapeutics

Protara Therapeutics to Participate in Upcoming Investor Conferences

4 months ago - By: Protara Therapeutics

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Protara Therapeutics

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Benzinga - Mentions: BCLI IBIO ABP HCTI ...

12 Health Care Stocks Moving In Monday's Intraday Session

5 months ago - By: Protara Therapeutics

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

5 months ago - By: Protara Therapeutics

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

5 months ago - By: Protara Therapeutics

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

5 months ago - By: Protara Therapeutics

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

6 months ago - By: Protara Therapeutics

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

7 months ago - By: Protara Therapeutics

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

7 months ago - By: Protara Therapeutics

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

8 months ago - By: Protara Therapeutics

Protara Highlights Recent Updates and Anticipated 2025 Milestones

9 months ago - By: Protara Therapeutics

Protara Announces Closing of $100 Million Public Offering

9 months ago - By: Protara Therapeutics

Protara Announces Pricing of $100 Million Public Offering

9 months ago - By: Protara Therapeutics

Protara Announces Proposed Public Offering

10 months ago - By: Protara Therapeutics

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

10 months ago - By: Protara Therapeutics

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

10 months ago - By: Protara Therapeutics

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

10 months ago - By: Protara Therapeutics

Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update